Idiopathic membranous nephropathy
Conditions
Interventions
test group:Colquhounia Root Tablets
Sponsors
Ruijin Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Patients with renal biopsy-confirmed diagnosis of idiopathic membranous nephropathy and positive renal tissue or serum anti-PLA2R antibodies; 2) Age =18 and =75 years old regardless of gender; 3) eGFR =30 ml/min/1.73m2; 4) 24-hour quantitative urine protein results still between 0.5-4 g after more than 3 months of treatment with a standard-dose ARB; the ARB specified in this trial was irbesartan; 5) Female patients of childbearing age with negative pregnancy test results and consent to use contraception; 6) Signed informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients who have received glucocorticoids and immunosuppressants (including but not limited to leflunomide, cyclophosphamide (CTX), cyclosporine, mycophenolate mofetil, tacrolimus, rituximab, etc.) within the last 3 months; 2.Patients with major comorbidities including chronic liver disease, cardiac insufficiency, severe cardiac arrhythmias, myocardial infarction, stroke, uncontrolled hypertension and diabetes, malignancies; 3.Patients with membranous nephropathy secondary to identifiable causes such as systemic lupus erythematosus, HBV/HCV infection, thyroid or other tumors, or organic solvent/heavy metal poisoning; 4.Patients who are pregnant (or planning pregnancy within 6 months), lactating; 5.Patients with known allergy to Torreyagrandis Root Tablets or contraindications for its use.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urine protein quantification at 24 hours; | — |
Secondary
| Measure | Time frame |
|---|---|
| Antiphospholipase A2 Antibody;Urine Protein; | — |
Countries
China
Contacts
Public ContactLiang ying
Xiyuan Hospital China Academy of Chinese Medical Sciences
Outcome results
None listed